there is a great need for compositions comprising FVIII that do not show any turbidity or other relevant impairment of quality like e.g. significant loss of activity before lyophilization and possess long term stability after lyophilization at the same time. As the requirements of a stable solution prior to lyophili...

The present disclosure provides antibodies that bind to interleukin-3 receptor alpha chain and uses thereof.

An apolipoprotein formulation is provided at a fixed dosage that is efficacious in the prophylactic and/or therapeutic treatment of diseases or conditions including but not limited to cardiovascular disease acute coronary syndrome atherosclerosis unstable angina pectoris and myocardial infarction. More particularly ...

The present invention relates to improved processes for purifying polypeptides of interest by increasing the amount of a polypeptide of interest bound to an ion-exchange matrix relative to the amount of one or more impurities bound to the ion-exchange matrix. This effect is achieved by adding a chemical compound in ...

The present invention relates to dosing regimens with half life extended Factor VIIa (FVIIa) for prophylactic and "on demand" treatment of bleeding as well as for preventing a bleeding episode during or after surgery in patients with congenital or acquired bleeding disorders. The present invention further relates to...

A method for inhibition of leukemic stem cells expressing IL-3R; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3R (CD123). The invention ...

A method for eliciting or inducing a protective immune response in a subject against a pandemic subtype of influenza virus comprises administering to the subject a composition comprising (i) at least one immunogen of an endemic influenza subtype, and (ii) an immunogen-free immunostimulating complex as adjuvant. ...

The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte colony stimulating factor receptor.

The present invention relates to prophylactic dosing regimens with long acting factor IX (FIX) in dosing intervals of 1 week or longer including (but not limited to) 10 days or longer such as two weeks three weeks or even monthly.

The present disclosure provides a CD131 binding protein comprising an antigen binding domain of an antibody wherein the antigen binding domain binds to or specifically binds to CD131 and neutralizes signaling by interleukin (IL) 3 IL 5 and granulocyte macrophage colony stimulating factor (GM CSF) and uses thereof. ...